Enter assignee name

CIPO Patents = 10

EPO Patents = 4

Trademarks = 16

Forward Citations = 3

Loading Chart...

35 inventors (with patents filed for the assignee):

Anthony Deodaunia William (7 out of 11 patents)

Brian William Dymock (4 out of 20 patents)

Stephanie Eliane Blanchard (3 out of 12 patents)

4. Harish Kumar Mysore Nagaraj (3 out of 7 patents)

5. Anders Poulsen (3 out of 12 patents)

6. Yee Ling Evelyn Tan (3 out of 7 patents)

7. Eric T Sun (3 out of 19 patents)

8. Cheng Hsia Angeline Lee (3 out of 7 patents)

9. Cheng H Lee (3 out of 3 patents)

10. Cheng Hsia Angelina Lee (1 out of 1 patent)

11. Valeria Livi (1 out of 9 patents)

12. Alberto Bernareggi (1 out of 9 patents)

13. Claudio Anasetti (1 patent)

14. Brian C Betts (0 patent)

15. Xuezhong Yu (0 patent)

8 patents: Sort by Forward Citations

1. 11135227 - Oxygen linked pyrimidine derivatives (2021-10-05),

2. 10517876 - Oxygen linked pyrimidine derivatives (2019-12-31),

3. 9624242 - 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2017-04-18),

4. 9573964 - Oxygen linked pyrimidine derivatives (2017-02-21),

5. 9211262 - Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity (2015-12-15),

6. 9062074 - (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt (2015-06-23),

7. 8987243 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt (2015-03-24),

8. 8980873 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2015-03-17),

CTI BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers. The company is dedicated to improving the lives of patients by advancing innovative treatments that address unmet medical needs. With a diverse pipeline of promising drug candidates, CTI BioPharma is at the forefront of cutting-edge research in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

8 Patents

#224 in Seattle, WA

#783 in Washington

#34,852 in US

Seattle, WA, United States of America

Cti Biopharma Corp.